KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity: 2016-2025

Historic Common Equity for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $9.3 billion.

  • Moderna's Common Equity fell 21.77% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 21.77%. This contributed to the annual value of $10.9 billion for FY2024, which is 21.32% down from last year.
  • Latest data reveals that Moderna reported Common Equity of $9.3 billion as of Q3 2025, which was down 0.73% from $9.4 billion recorded in Q2 2025.
  • Over the past 5 years, Moderna's Common Equity peaked at $19.1 billion during Q4 2022, and registered a low of $3.8 billion during Q1 2021.
  • In the last 3 years, Moderna's Common Equity had a median value of $11.9 billion in 2024 and averaged $12.7 billion.
  • As far as peak fluctuations go, Moderna's Common Equity spiked by 452.32% in 2021, and later tumbled by 32.05% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Common Equity stood at $14.1 billion in 2021, then surged by 35.19% to $19.1 billion in 2022, then dropped by 27.55% to $13.9 billion in 2023, then declined by 21.32% to $10.9 billion in 2024, then declined by 21.77% to $9.3 billion in 2025.
  • Its Common Equity stands at $9.3 billion for Q3 2025, versus $9.4 billion for Q2 2025 and $10.1 billion for Q1 2025.